ETF Holdings Breakdown of EYPT

Stock Name	Eyepoint Pharmaceuticals Inc
Ticker	EYPT(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US30233G2093
LEI	549300QE1RU34T50MR69

EYPT institutional holdings

The adjusted close for EYPT on 2025-11-11 was 11.65

The following institutional investment holdings of EYPT have been identified

Date ETF ISIN/Name Num Shares Book value Derived Price per Share Comment
2025-11-11 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 44,275 USD 515,582 11.64 Incorrect share price reported. Should be 11.65 not 11.64. May be due to incorrect reporting of currency . Could be EUR or USD instead

2025-11-11 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 44,275 USD 515,582 2.5% 11.64

Total = 88,550 USD 1,031,164
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share
2025-11-11	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	44,275	USD 515,582	11.64
2025-11-11	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	44,275	USD 515,582 2.5%	11.64
Total =	88,550	USD 1,031,164

News associated with EYPT

Brokerages Set Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Target Price at $26.86: Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) has been given an average recommendation of “Buy” by the seven analysts that are presently covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have updated their coverage on the stock […] - 2025-09-22 02:42:50
Brokerages Set Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Price Target at $25.38: Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) has earned a consensus recommendation of “Buy” from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have covered the stock in the last year […] - 2025-08-28 03:12:50
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Down After Earnings Miss: Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) gapped down before the market opened on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $10.89, but opened at $9.82. Eyepoint Pharmaceuticals shares last traded at $10.42, with a volume of 189,142 shares trading hands. The company reported ($0.85) […] - 2025-08-08 02:44:51
Royal Bank Of Canada Begins Coverage on Eyepoint Pharmaceuticals (NASDAQ:EYPT): Equities research analysts at Royal Bank Of Canada began coverage on shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) in a research report issued on Tuesday, Marketbeat reports. The firm set an “outperform” rating and a $28.00 price target on the stock. Royal Bank Of Canada’s price objective would suggest a potential upside of […] - 2025-06-19 02:42:47
Two Sigma Advisers LP Decreases Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT): Two Sigma Advisers LP cut its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) by 37.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 104,500 shares of the company’s stock after selling 62,000 shares during […] - 2025-06-03 05:00:52
Two Sigma Investments LP Sells 103,098 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT): Two Sigma Investments LP reduced its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) by 22.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 353,954 shares of the company’s stock after selling 103,098 shares during the quarter. Two […] - 2025-06-01 05:52:45
EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Lowered to $26.00 at Mizuho: EyePoint Pharmaceuticals (NASDAQ:EYPT – Free Report) had its price objective decreased by Mizuho from $30.00 to $26.00 in a research note published on Friday,Benzinga reports. Mizuho currently has an outperform rating on the stock. A number of other equities analysts also recently issued reports on the stock. StockNews.com upgraded shares of EyePoint Pharmaceuticals to a […] - 2025-05-19 02:46:48
Tower Research Capital LLC TRC Cuts Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT): Tower Research Capital LLC TRC cut its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) by 53.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 4,581 shares of the company’s stock after selling 5,241 shares during the period. Tower Research Capital LLC TRC’s holdings […] - 2025-05-15 05:38:48
Schonfeld Strategic Advisors LLC Acquires New Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT): Schonfeld Strategic Advisors LLC acquired a new stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 12,200 shares of the company’s stock, valued at approximately $91,000. Other hedge funds and other […] - 2025-05-15 04:56:50
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Sold by Renaissance Technologies LLC: Renaissance Technologies LLC reduced its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) by 26.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 137,500 shares of the company’s stock after selling 49,937 shares during the period. Renaissance Technologies LLC’s holdings in […] - 2025-05-01 05:31:09
Legal & General Group Plc Boosts Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT): Legal & General Group Plc grew its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) by 4.4% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 46,263 shares of the company’s stock after purchasing an additional 1,932 shares during the period. Legal & General Group Plc’s holdings in EyePoint Pharmaceuticals were […] - 2025-05-01 04:45:01
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives $26.63 Average Target Price from Analysts: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) has received a consensus rating of “Buy” from the nine ratings firms that are presently covering the stock, MarketBeat reports. Nine analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have updated their coverage on the stock in […] - 2025-04-25 02:52:46
Wellington Management Group LLP Acquires 5,552 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT): Wellington Management Group LLP lifted its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) by 3.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 177,316 shares of the company’s stock after buying an additional 5,552 shares during the period. Wellington Management Group LLP’s holdings in EyePoint Pharmaceuticals were worth $1,321,000 at the […] - 2025-04-14 04:50:52
Brokerages Set EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) PT at $26.63: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) has received a consensus rating of “Buy” from the nine brokerages that are currently covering the firm, MarketBeat.com reports. Nine equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have issued a report on the stock […] - 2025-03-31 02:46:59
Intech Investment Management LLC Acquires 6,137 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT): Intech Investment Management LLC boosted its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) by 36.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,105 shares of the company’s stock after buying an additional 6,137 shares during the quarter. Intech Investment Management […] - 2025-03-28 06:30:47
China Universal Asset Management Co. Ltd. Has $108,000 Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT): China Universal Asset Management Co. Ltd. grew its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) by 40.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,472 shares of the company’s stock after buying an additional 4,179 shares during the quarter. China Universal […] - 2025-02-04 07:14:53

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.